The key themes of France’s latest initiative on shortages are repatriating the production of certain essential medicines and their active substances, earlier detection of potential supply problems, and more effective and transparent communications with all actors in the supply chain.
Many medicines may be in short supply, but there is no shortage of ideas about how to deal with them. A case in point is France, where the government has just come up with yet another set of proposals in the form of a new “roadmap” to 2027.
Among the measures envisaged are better ways of anticipating shortages, a list of “medicines of major therapeutic interest” (MMTIs), and...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
